1. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet [Internet]. 2021 [cited 2022 Jun 24];398:213–22. http://www.thelancet.com/article/S014067362101429X/fulltext.
2. al Kaabi N, Zhang Y, Xia S, Yang Y, al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 Infection in adults: a randomized clinical trial. JAMA [Internet]. 2021 [cited 2022 Jun 24];326:35–45. https://jamanetwork.com/journals/jama/fullarticle/2780562.
3. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 covid-19 vaccine. N Engl J Med [Internet]. 2021;385:1172–83. https://doi.org/10.1056/NEJMoa2107659. (cited 2022 Jun 24).
4. Logunov DY, Dolzhikova I v., Shcheblyakov D v., Tukhvatulin AI, Zubkova O v., Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet [Internet]. 2021 [cited 2022 Jun 24];397:671–81. https://pubmed.ncbi.nlm.nih.gov/33545094/.
5. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N Engl J Med [Internet]. 2021;384:2187–201. https://doi.org/10.1056/NEJMoa2101544. (cited 2022 Jun 24).